is in suspended animation in anticipation

SIE has been sitting almost at the one price level for 5 days now waiting for some good news ,

It could be good news and lead to a increase in profits If not watch out for the mass exit .






News extracts below

______________________________________



ASX Announcement and Media Release
19 July 2004
SciGen Limited
SCIGEN’S INSULIN APPROVED FOR SALE IN INDIA
SciGen Limited (“SciGen”) has received regulatory approval from the Drug Controller of India for
commercial sale of its recombinant human insulin SciLin TM.
SciGen managing director and chief executive officer, Mr Mark Compton said the approval was a key milestone for SciGen.
“The insulin market in India is very large with the incidence of diabetes in the country estimated
at approximately 8per cent and rising,” Mr Compton said.
“In addition, medical treatment is becoming much more affordable in India as one consequence
of India being one of the fastest growing economies in the Asia Pacific Region, if not the World,”
Mr Compton added.

SciGen’s partners in India, Shreya Life Sciences and Ranbaxy Laboratories have indicated that
each of their companies is ready to take SciGen’s insulin to the Indian market soon after supply
is received, which is expected in a few weeks.
SciGen has commercialisation agreements in place with Ranbaxy, India’s largest
pharmaceutical company and a global giant in generic drugs, and Shreya Life Sciences for
marketing and sales of SciLin in India.

The combined sales force available to SciGen for insulin sales by virtue of these agreements,
approximates 3,500 medical sales representatives, visiting about 2 million doctors in total.

In addition to this approval for insulin in India, SciGen has recently received approval for its
human growth hormone, SciTropin TM in India and steps are being taken to launch the product
within the next 90 days.
Working with SciGen’s partner in China, the company has also recently submitted the registration dossier for human insulin.
The agreement with SciGen’s commercial partner in

China comprehends minimum sales of US$21M over three years following registration.
Mr Compton said the registration of human insulin in India represented a very significant
success for SciGen’s already-proven regulatory affairs team.
“The registration of biological pharmaceuticals in particular is a highly specialist area and
SciGen’s team has demonstrated again that the company has these skills and can use them to
the benefit of SciGen’s stakeholders,” Mr Compton said.
***************************************




_________________
ASX Announcement and Media Release
29 June 2004
SciGen Limited
Potential Strategic Investment in SciGen
The Directors of SciGen Limited (“SciGen” or “the Company”) announced today that the
Company is in discussions with another party regarding a potential strategic investment in
SciGen.
Whilst the terms of the potential investment are not yet finalised, a due diligence review is underway.
Further announcements regarding progress with this potential transaction will be made at the
appropriate time.
About SciGen
SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later
stage research. It co-develops and markets genetically engineered biopharmaceutical
products for human healthcare. SciGen focuses in the areas of gastroenterology,
endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.
SciGen acquires rights to manufacture, distribute and market biopharmaceutical products
under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary
biotechnology-derived products, and biogeneric products, which can allow for faster entry
into the market, as biogeneric products have undergone much of the clinical development
and trials required to bring new drugs to market. This minimises the risks associated with
early stage product development. SciGen currently undertakes R&D activities in collaboration
with strategic partners and institutions.
SciGen’s competitive advantage is in identifying research with commercial potential at an
early stage to which it adds its expertise in gaining regulatory approval and bringing products
to market